How to Get Jatenzo in Kansas

Kansas Telehealth Rules Allow Jatenzo Prescribing

Kansas law permits licensed prescribers to write Schedule III controlled substance prescriptions through telehealth, which means a patient in Wichita, Topeka, or a rural county can receive a Jatenzo prescription without driving to a clinic. The Kansas State Board of Healing Arts requires the telehealth provider to hold an active Kansas medical license or be registered through an interstate compact.

A synchronous video visit satisfies the patient-provider relationship requirement. Audio-only encounters may not qualify for initial controlled substance prescriptions under current Kansas Board of Pharmacy guidance. Patients should confirm that their telehealth platform uses a provider licensed specifically in Kansas, not merely a provider licensed in a neighboring state like Missouri or Colorado, because a prescription written by an out-of-state provider who lacks Kansas licensure cannot be filled at a Kansas pharmacy for a CIII substance.

HealthRX connects Kansas patients with board-certified clinicians who evaluate testosterone levels, review symptoms, and prescribe Jatenzo when clinically appropriate. The initial visit typically includes a lab order, symptom review, and medical history assessment.

Who Can Prescribe Jatenzo in Kansas

Three categories of prescribers in Kansas can write a Jatenzo prescription: physicians (MD/DO), advanced practice registered nurses (APRNs), and physician assistants (PAs). Each has prescriptive authority for Schedule III substances under Kansas statute K.S.A. 65-1130.

APRNs in Kansas prescribe under a collaborative practice agreement with a physician, but this agreement does not require the physician to co-sign each prescription. PAs similarly operate under a supervisory agreement. In practical terms, a Kansas patient may see an NP or PA for their Jatenzo prescription without needing a separate physician visit.

Endocrinologists and urologists most commonly prescribe Jatenzo, but primary care physicians, sports medicine doctors, and men's health specialists also write prescriptions regularly. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by two morning serum total testosterone measurements below 300 ng/dL [1]. That threshold applies regardless of prescriber type.

Lab Work Required Before a Kansas Prescription

Before any Kansas prescriber initiates Jatenzo, standard of care requires specific laboratory confirmation. The minimum lab panel includes two fasting morning total testosterone levels drawn on separate days, each falling below 300 ng/dL per the Endocrine Society guideline [1].

Most prescribers also order a baseline metabolic panel that includes:

• Complete blood count (CBC) with hematocrit, because testosterone therapy raises red blood cell mass. The FDA label for Jatenzo warns against initiation if hematocrit exceeds 54% [2].
• Lipid panel, since oral testosterone undecanoate can reduce HDL cholesterol. In the Swerdloff et al. registration trial, mean HDL decreased by approximately 3.3 mg/dL from baseline at 12 months [3].
• Hepatic function panel, although Jatenzo's lipid-based oral absorption pathway avoids first-pass hepatotoxicity seen with older 17-alpha-alkylated oral androgens.
• PSA for men over 40 or those with a family history of prostate cancer.
• LH and FSH, to distinguish primary from secondary hypogonadism.

Quest Diagnostics and Labcorp both operate draw sites across Kansas, including locations in Kansas City, Wichita, Overland Park, Lawrence, and Manhattan. Telehealth providers can send lab orders electronically to any of these sites, and results typically return within 48 to 72 hours.

How Jatenzo Differs from Injectable Testosterone

Jatenzo earned FDA approval in March 2019 as the first oral testosterone undecanoate capsule for male hypogonadism in the United States [2]. Its lipid-based formulation absorbs through the intestinal lymphatic system, bypassing hepatic first-pass metabolism. That mechanism distinguishes it from methyltestosterone, which the FDA approved decades earlier but which carries significant liver toxicity risk.

The key trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and demonstrated that 87% of patients achieved average serum testosterone concentrations within the normal range (300 to 1 to 100 ng/dL) at the 237 mg twice-daily dose after titration [3]. The starting dose is 158 mg twice daily taken with food, titrated at approximately day 21 based on serum testosterone levels.

Compared to intramuscular testosterone cypionate (the most prescribed formulation in the U.S.), Jatenzo offers three practical advantages for Kansas patients:

1. No injections. Patients who are needle-averse or who lack access to a clinic for intramuscular administration can self-administer oral capsules at home.
2. Steady-state pharmacokinetics. Twice-daily dosing produces less peak-to-trough testosterone fluctuation than biweekly intramuscular injections, which can swing testosterone from supraphysiologic peaks to subtherapeutic troughs [4].
3. No risk of transdermal transfer. Unlike topical gels (AndroGel, Testim), Jatenzo carries zero risk of skin-to-skin testosterone transfer to partners or children.

The primary disadvantage is cost. Generic testosterone cypionate costs $30 to $60 per month, while Jatenzo without insurance ranges from $700 to $900.

Kansas Medicaid Does Not Cover Jatenzo for Hypogonadism

Kansas Medicaid's preferred drug list does not include Jatenzo for male hypogonadism. Coverage exists only for a narrow type 2 diabetes-related indication, which excludes the vast majority of men seeking testosterone replacement. This means Kansas Medicaid beneficiaries who need testosterone therapy will likely be directed toward injectable testosterone cypionate or topical formulations that carry Medicaid coverage.

For commercially insured patients, most Kansas plans (Blue Cross Blue Shield of Kansas, Aetna, UnitedHealthcare) require prior authorization before covering Jatenzo. The prior authorization process typically demands:

• Documentation of two morning total testosterone levels <300 ng/dL
• Evidence of hypogonadal symptoms (fatigue, decreased libido, erectile dysfunction, loss of muscle mass)
• Notation that the patient has tried or has a contraindication to injectable testosterone or topical gel
• A diagnosis code of E29.1 (testicular hypofunction) on the claim

Turnaround time for prior authorization in Kansas averages 3 to 7 business days. If denied, patients can appeal. Tolmar's Jatenzo savings program may reduce out-of-pocket costs for commercially insured patients to as low as $75 per month, though eligibility varies.

Filling a Jatenzo Prescription at Kansas Pharmacies

Jatenzo is a branded product stocked at most retail chain pharmacies in Kansas, including CVS, Walgreens, and Hy-Vee Pharmacy. Specialty pharmacies such as Optum Specialty and AllianceRx Walgreens also dispense it and may offer better pricing or direct manufacturer coordination.

Because Jatenzo is a Schedule III controlled substance, Kansas law requires that the prescription include the prescriber's DEA number and that the dispensing pharmacy verify the prescription against the Kansas Prescription Drug Monitoring Program (K-TRACS) database [5]. Pharmacists must check K-TRACS before dispensing any CIII substance, a step that adds only minutes to the process but protects against diversion.

Kansas-licensed 503A compounding pharmacies can compound oral testosterone undecanoate capsules as a patient-specific preparation if a prescriber writes a prescription specifying a compounded formulation. Compounded versions cost significantly less than brand Jatenzo, often $150 to $300 per month. The trade-off is that compounded preparations have not undergone FDA bioequivalence testing, so absorption and testosterone levels may vary between batches.

503A pharmacies in Kansas can ship compounded testosterone undecanoate within the state. Interstate shipping of compounded CIII substances requires the pharmacy to hold licenses in both the originating and receiving states, which limits out-of-state compounding options.

Cardiovascular Monitoring on Jatenzo

The FDA added a class-wide boxed warning to all testosterone products in 2015 regarding cardiovascular risk, and Jatenzo carries an additional specific warning about blood pressure elevation [2]. In the Swerdloff et al. trial, systolic blood pressure increased by a mean of 3 to 5 mmHg in the treatment group compared to baseline [3].

A 2023 trial, TRAVERSE (N=5,246), provided the first large-scale randomized cardiovascular safety data for testosterone therapy [6]. TRAVERSE used transdermal testosterone gel (not Jatenzo specifically), but its findings inform the risk-benefit discussion for all testosterone formulations. The trial found no statistically significant increase in major adverse cardiovascular events (MACE) over a median follow-up of 33 months: the hazard ratio was 0.96 (95% CI: 0.78 to 1.17) [6].

Kansas prescribers should monitor:

• Blood pressure at baseline, 3 months, and every 6 to 12 months thereafter
• Hematocrit at 3 to 6 months, then annually. If hematocrit exceeds 54%, dose reduction or therapeutic phlebotomy is warranted per the Endocrine Society guideline [1]
• Lipid panel at 6 to 12 months, given Jatenzo's effect on HDL cholesterol
• PSA annually for men over 40

Dr. Ronald Swerdloff, lead investigator of the Jatenzo registration trial, noted in the Journal of Clinical Endocrinology & Metabolism: "Oral testosterone undecanoate provides a practical alternative to injections and gels, with a cardiovascular and hepatic safety profile that warrants standard monitoring rather than avoidance" [3].

Timeline from First Visit to Receiving Jatenzo in Kansas

The typical timeline breaks down into discrete steps. Lab work takes 2 to 3 days from draw to result. A follow-up telehealth visit to review labs and write the prescription takes 1 day. Prior authorization, if required by the patient's insurer, adds 3 to 7 business days. Pharmacy dispensing after authorization takes 1 to 2 business days for retail pharmacies, or 3 to 5 business days for specialty or mail-order pharmacies.

Total elapsed time from initial consultation to capsules in hand: 7 to 17 business days for most commercially insured Kansas patients. Cash-pay patients who skip prior authorization can receive Jatenzo in as few as 3 to 5 days.

Patients in rural Kansas counties (e.g., Haskell, Greeley, Wallace) where retail pharmacy options are limited can use mail-order specialty pharmacies. Express Scripts, CVS Caremark, and Optum all ship CIII medications to Kansas addresses with signature-required delivery.

Kansas-Specific Prescribing Considerations

Kansas adopted the Interstate Medical Licensure Compact, which allows physicians licensed through the Compact to practice telehealth across member states without obtaining a separate Kansas license. This expands the pool of available Jatenzo prescribers for Kansas residents, particularly those in underserved western Kansas counties where endocrinologists are scarce.

The Kansas Board of Pharmacy permits 90-day fills for Schedule III substances, meaning patients can reduce pharmacy visits to four per year. This is a practical consideration for patients who live far from their nearest pharmacy.

Kansas does not impose state-level restrictions on testosterone prescribing beyond federal DEA requirements. There is no mandatory waiting period, no state-specific dosage cap, and no requirement for in-person visits before telehealth prescribing of CIII substances, provided the prescriber establishes an adequate patient-provider relationship during the synchronous video visit.

The American Urological Association's 2018 guideline recommends re-evaluating testosterone therapy at 3 to 6 months and discontinuing treatment if symptoms have not improved [7]. Kansas prescribers should document symptom response using a validated instrument such as the Aging Males' Symptoms (AMS) scale or the quantitative Androgen Deficiency in Aging Males (qADAM) questionnaire at baseline and follow-up.